Community exercise program aims to boost health in older adults with multiple chronic conditions
NCT ID NCT06771024
First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times
Summary
This study tests a community-based exercise program for people aged 50 and older who have at least two chronic conditions, such as heart disease, diabetes, arthritis, or obesity. The program is designed to improve muscle strength, heart and lung fitness, and overall well-being. Researchers will compare the exercise group to a control group to see if personalized exercise plans lead to better health outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
A research network
The lead sponsor is a research network or cooperative group.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged ≥50 years; * At least 2 of the following: Prior cardiovascular disease (\>12 months); High cardiovascular risk (SCORE2 or SCORE2 O.P.); Post-stroke (ischemic or hemorrhagic) with treated etiology; Type 2 Diabetes (\> 6 months, ADA); Osteoarthristis (clinical signs/symptoms, NICE); Overweight/Obesity (BMI ≥ 27 kg/m2). * Autonomous walking. * Able to provide informed consent. * Stable medications for ≥ 3 months (related to diagnoses of interest). * Physical activity below WHO recommendations. * No contraindications to exercise (cardiovascular, cerebrovascular, respiratory, musculoskeletal) according to ACSS. Exclusion Criteria: * Moderate to severe cognitive impairment - Montreal Cognitive Assessment (MoCA). * Type 2 Myocardial Infarction. * Class III or IV angina (Canadian Cardiovascular Society). * Class III or IV angina (New York Heart Association). * Uncontrolled CVD: symptomatic arrhythmias with hemodynamic compromise; severe symptomatic aortic valve stenosis; uncontrolled symptomatic heart failure; endocarditis, pericarditis, or active myocarditis; acute aortic syndrome; suspected or known dissecting aneurysm; acute systemic infections. * Pacemaker user. * Neurological disorders affecting gait. * Severe diabetes-related complications contraindicating exercise (poor metabolic control, diabetic foot, diabetic retinopathy, diabetic nephropathy, and diabetic autonomic neuropathy). * Recent use of insulin or sulphonylureas (\< 3 months). * Untreated stroke etiology: indication for revascularization; non-anticoagulated atrial fibrillation; intracranial atherosclerotic occlusive disease. * Musculoskeletal or ocular conditions preventing strength training (acute herniated disc, fractures, recent spinal surgery, glaucoma with elevated intraocular pressure). * Terminal illness. * Inability to understand basic oral or written Portuguese. * Participation in supervised dietary intervention.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiovascular disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Algarve Biomedical Center
Faro, Algarve, 8005-139, Portugal
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill takes aim at stubborn blood sugar
- Can a checklist and heart monitor stop repeat strokes?
- Gene therapy shots aim to save legs from amputation in diabetes
- Heart hole or stroke trigger? global registry tracks who gets closure and what happens next
- Zapping the spine while wearing a robotic ankle: a new way to help kids walk?
- Can a nurse and a neighbor help tame chronic disease?